Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

Bridgeman, VL, Vermeulen, PB, Foo, S et al. (19 more authors) (2017) Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. The Journal of Pathology, 241 (3). pp. 362-374. ISSN 0022-3417

Abstract

Metadata

Authors/Creators:
  • Bridgeman, VL
  • Vermeulen, PB
  • Foo, S
  • Bilecz, A
  • Daley, F
  • Kostaras, E
  • Nathan, MR
  • Wan, E
  • Frentzas, S
  • Schweiger, T
  • Hegedus, B
  • Hoetzenecker, K
  • Renyi-Vamos, F
  • Kuczynski, EA
  • Vasudev, NS https://orcid.org/0000-0001-8470-7481
  • Larkin, J
  • Gore, M
  • Dvorak, HF
  • Paku, S
  • Kerbel, RS
  • Dome, B
  • Reynolds, AR
Copyright, Publisher and Additional Information: © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: Lung metastasis; angiogenesis; vessel co-option; anti-angiogenic therapy; sunitinib; drug resistance
Dates:
  • Published: February 2017
  • Accepted: 18 October 2016
  • Published (online): 9 November 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP)
Depositing User: Symplectic Publications
Date Deposited: 12 Jan 2017 12:20
Last Modified: 05 Oct 2017 16:27
Published Version: http://doi.org/10.1002/path.4845
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/path.4845

Share / Export

Statistics